|
Go to download area
The Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition
65 or the Act) requires the Governor to publish, and update at least
annually, a list of chemicals known to the State to cause cancer
or reproductive toxicity. The Act provides two mechanisms for administratively
listing chemicals as known to the State to cause cancer or reproductive
toxicity (Health and Safety Code
Section 25249.8(b)).
One mechanism by which a chemical is listed is if a body considered
to be authoritative by the state's qualified experts has formally
identified it as causing cancer or reproductive toxicity. For carcinogenicity,
the US Environmental Protection Agency (US EPA), the International
Agency for Research on Cancer (IARC), the National Toxicology Program
(NTP), the Food and Drug Administration (FDA), and the National
Institute for Occupational Safety and Health (NIOSH) have been identified
as authoritative bodies for purposes of the Act. The criteria for
listing chemicals through the "authoritative bodies" mechanism
are set forth in Title 22, California Code of Regulations (22 CCR)
Section 12306.
The second mechanism for the administrative listing of a chemical
applies if an agency of state or federal government has formally
required that the chemical be labeled or identified as causing cancer
or reproductive toxicity. The criteria for listing chemicals through
this mechanism are set forth in 22 CCR Section
12902.
As the lead agency for the implementation of Proposition 65, the
Office of Environmental Health Hazard Assessment (OEHHA) of the
California Environmental Protection Agency is investigating the
possible listing of the chemicals identified below, based upon information
in the references cited. Documentation summarizing the rationale
for considering the evaluation of these chemicals for possible administrative
listing is available from OEHHA's Proposition 65 Implementation
Office at the address and telephone number indicated below, or from
the Internet at the following address: http://www.oehha.ca.gov/.
OEHHA is committed to public participation and external scientific
peer review in its implementation of Proposition 65, and welcomes
public input on this listing process. As part of its efforts to
ensure that regulatory decisions are based upon a thorough consideration
of all relevant information, OEHHA is soliciting information which
may be relevant to the evaluation of these chemicals in the context
of the Proposition 65 administrative listing regulatory criteria
(22 CCR Section 12306 or
Section 12902, as appropriate).
A public forum will be held on Thursday, October 26, 2000,
to provide an opportunity for interested parties to present oral
comments and to discuss the scientific data and other information
relevant to a determination as to whether these chemicals meet the
criteria for listing set forth in 22 CCR Section 12306 or Section
12902. The public forum will begin at 10:00 a.m. at 1515 Clay Street,
Elihu Harris State Building, Conference Room A, Oakland, California
[map]
and will last until all business has been conducted or until 5:00
p.m.
Written comments provided in triplicate, along with supporting
information, may also be submitted to:
Cynthia Oshita
Office of Environmental Health Hazard Assessment
1001 I Street,
Sacramento, CA 95814
FAX: (916) 327-1097
Telephone: (916) 445-6900
In order to be considered, comments must be postmarked (if sent
by mail) or received at OEHHA (if hand-delivered or sent by fax)
by 5:00 p.m. Tuesday, November 28, 2000.
Following the review of all comments received, OEHHA will announce
its intention to proceed with the listing of those candidate chemicals
that meet the regulatory criteria for administrative listing in
a Notice of Intent to List Chemicals.
A. Chemicals which may meet the criteria set forth in 22 CCR Section
12306 for listing as known to cause carcinogenicity via the "authoritative
bodies" mechanism:
| Chemical |
CAS No. |
Reference |
|
Catechol
|
120-80-9
|
IARC (1999a)
|
|
DEF (S,S,S-tributyl phosphorotrithioate; Tribufos)
|
78-48-8
|
U.S. EPA (1997c)
|
|
Ethoprop
|
13194-48-4
|
U.S. EPA (1997a)
|
|
Indium phosphide
|
22398-80-7
|
NTP (2000a; 2000c)
|
|
Lynestrenol
|
52-76-6
|
IARC (1999b)
|
|
Naphthalene
|
91-20-3
|
NTP (2000b; 2000c)
|
|
Norethynodrel
|
68-23-5
|
IARC (1999b)
|
|
Propachlor
|
1918-16-7
|
U.S. EPA (1997b)
|
|
Strong inorganic acid mists containing sulfuric
acid
|
7664-93-9 (sulfuric acid)
|
NTP (2000d)
|
B. Chemicals which may meet the criteria set forth in 22 CCR Section
12902 for listing as known to cause cancer and/or reproductive toxicity
via the "formally required to be labeled or identified"
mechanism:
| Chemical |
CAS No. |
Toxicological Endpoints |
References |
|
Albuterol
|
18559-94-9
|
Developmental toxicity
|
FDA (1986)
|
|
Amantadine hydrochloride
|
665-66-7
|
Developmental toxicity
|
FDA (1993a)
|
|
Atorvastatin calcium
|
134523-03-8
|
Developmental toxicity
|
FDA (1998a)
|
|
Diazoxide
|
364-98-7
|
Developmental toxicity
|
FDA (1994a)
|
|
Dichlorphenamide
|
120-97-8
|
Developmental toxicity
|
FDA (1994b)
|
|
Diltiazem hydrochloride
|
42399-41-7
|
Developmental toxicity
|
FDA (1996b)
|
|
Famciclovir
|
104227-87-4
|
Male reproductive toxicity
|
FDA (1997a)
|
|
Felodipine
|
72509-76-3
|
Developmental toxicity Female reproductive toxicity
|
FDA (1998b)
|
|
Filgrastim
|
121181-53-1
|
Developmental toxicity
|
FDA (1992)
|
|
Fluvastatin sodium
|
93957-55-0
|
Developmental toxicity Male reproductive toxicity
|
FDA (1999)
|
|
Nimodipine
|
66085-59-4
|
Developmental toxicity
|
FDA (1996c)
|
|
Ribavirin*
|
36791-04-5
|
Male reproductive toxicity
|
FDA (1993b)
|
|
Rifampin
|
13292-46-1
|
Developmental toxicity Female reproductive toxicity
|
FDA (1997b)
|
|
Trientine hydrochloride
|
38260-01-4
|
Developmental toxicity
|
FDA (1988)
|
* Ribavirin was added to the list of chemicals known
to cause reproductive toxicity on the basis of a developmental toxicity
endpoint on April 1, 1990.
Follow
this link to download the documentation on the chemicals which
may meet the criteria set forth in 22 CCR Section 12306 for listing
as known to cause carcinogenicity via the "authoritative bodies"
mechanism
Follow this link to download
the documentation on chemicals which may meet the criteria set forth
in 22 CCR Section 12902 for listing as known to cause cancer and/or
reproductive toxicity via the "formally required to be labeled
or identified" mechanism
Follow this link to download
a copy of this notice.
References
Blanzat-Reboud D, Russfield AB (1969). Effect of parenteral
steroids on induction of tumors in mice by 2-methylcholanthrene.
Am J Obstet Gynecol 103: 96-101.
California Department of Pesticide Regulation (1999).
Evaluation of S,S,S-Tributyl phosphorotrithioate (DEF) as a Toxic
Air Contaminant. Part C. Human Health Assessment found at URL http://www.cdpr.ca.gov/docs/empm/pubs/def/defaircn.htm.
Committee on Safety of Medicines (1972). Carcinogenicity
Tests of Oral Contraceptives. London, Her Majesty's Stationery Office.
Food and Drug Administration (FDA, 1986). Final printed
labeling for the drug albuterol. FDA approved 1986.
Food and Drug Administration (FDA, 1993a). Final printed
labeling for the drug amantadine hydrochloride. FDA approved 1993.
Food and Drug Administration (FDA, 1998a). Final printed
labeling for the drug atorvastatin calcium. FDA approved 1998.
Food and Drug Administration (FDA, 1994a). Final printed
labeling for the drug diazoxide. FDA approved 1994.
Food and Drug Administration (FDA, 1994b). Final printed
labeling for the drug dichlorphenamide. FDA approved 1994.
Food and Drug Administration (FDA, 1996b). Final printed
labeling for the drug diltiazem hydrochloride. FDA approved 1996.
Food and Drug Administration (FDA, 1997a). Final printed
labeling for the drug famciclovir. FDA approved 1997.
Food and Drug Administration (FDA, 1998b). Final printed
labeling for the drug felodipine. FDA approved 1998.
Food and Drug Administration (FDA, 1992). Final printed
labeling for the drug filgrastim. FDA approved 1992.
Food and Drug Administration (FDA, 1999). Final printed
labeling for the drug fluvastatin sodium. FDA approved 1999.
Food and Drug Administration (FDA, 1996c). Final printed
labeling for the drug nimodipine. FDA approved 1996.
Food and Drug Administration (FDA, 1993b). Final printed
labeling for the drug ribavirin. FDA approved 1993.
Food and Drug Administration (FDA, 1997b). Final printed
labeling for the drug rifampin. FDA approved 1997.
Food and Drug Administration (FDA, 1988). Final printed
labeling for the drug trientine hydrochloride. FDA approved 1988.
Hirose M, Fukushima S, Shirai T, Hasegawa R, Kato
T, Tanaka H, Asakwa E, Ito N (1990). Stomach carcinogenicity of
caffeic acid, sesamol and catechol in rats and mice. Jpn J Cancer
Res 81: 207-212.
Hirose M, Fukushima S, Tanaka H, Asakawa E, Takahashi
S, Ito N (1993). Carcinogenicity of catechol in F344 rats and B6C3F1
mice. Carcinogenesis 14: 525-529.
International Agency for Research on Cancer (IARC,
1979). IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans. Volume 21: 407-415 and 461-477. Sex Hormones (II). IARC,
Lyon France.
International Agency for Research on Cancer (IARC,
1992). IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans. Volume 54: 41-119. Occupational Exposures to Mists and Vapours
from Strong Inorganic Acids; and Other Industrial Chemicals. IARC,
Lyon France.
International Agency for Research on Cancer (IARC,
1999a). IARC Monographs on the Evaluation of Carcinogenic Risks
to Humans. Volume 71: 433-452. Re-evaluation of Some Organic Chemicals,
Hydrazine and Hydrogen Peroxide (Part Two). IARC, Lyon France.
International Agency for Research on Cancer (IARC,
1999b). IARC Monographs on the Evaluation of Carcinogenic Risks
to Humans. Volume 72: 49-338. Hormonal Contraception and Post-Menopausal
Hormonal Therapy. IARC, Lyon France.
Misdorp W (1991). Progestogens and mammary tumors
in dogs and cats. Acta Endocrinol 125: 27-31.
National Toxicology Program (NTP, 2000a). Toxicology
and Carcinogenesis Studies of Indium Phosphide (CAS No. 22398-80-7)
in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Board Draft.
NTP Technical Report Series No. 499. NTIS Publication No. 00-4433.
U.S. Department of Health and Human Services, NTP, Research Triangle
Park, NC.
National Toxicology Program (NTP, 2000b). Toxicology
and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3) in F344/N
Rats (Inhalation Studies). NTP Technical Report Series No. 500.
NTIS Publication No. 00-4434. U.S. Department of Health and Human
Services, NTP, Research Triangle Park, NC.
National Toxicology Program (NTP, 2000c). Summary
Minutes from Peer Review of Draft Technical Reports of Long-Term
Toxicology and Carcinogenesis Studies by the Technical Reports Review
Subcommittee on May 18, 2000. NTP, Research Triangle Park, NC.
National Toxicology Program (NTP, 2000d). Ninth Report
on Carcinogens as reported on the NTP website at http://ntp-server.niehs.nih/gov.
Rudali G (1975). Induction of tumors in mice with
synthetic sex hormones. Gann Monogr 17: 243-252.
Schuppler J, Gunzel P (1979). Liver tumors and steroid
hormones in rats and mice. Arch Toxicol Suppl 2: 181-195.
Siemiatycki J (ed). (1991). Risk Factors for Cancer
in the Workplace. Boca Raton, FL, CRC Press.
Soskolne CL, Zeighami EA, Hanis NM, Kupper LL, Herrmann
N, Amsel J, Mausner JS, Stellman JM (1984). Laryngeal cancer and
occupational exposure to sulfuric acid. Am J Epidemiol 120: 358-369.
Soskolne CL, Jhangri GS, Siemiatycki J, Lakhani R,
Dewar R, Burch JD, Howe GR, Miller AB (1992). Occupational exposure
to sulfuric acid in southern Ontario, Canada, in association with
laryngeal cancer. Scand J Work Environ Health 18: 225-32.
Steenland K (1997). Laryngeal cancer incidence among
workers exposed to acid mists (United States). Cancer Causes Control
8: 34-8.
Steenland K, Beaumont J (1989). Further follow-up
and adjustment for smoking in a study of lung cancer and acid mists.
Am J Ind Med 16: 347-354.
Steenland K, Schnorr T, Beaumont J, Halperin W, Bloom
T (1988). Incidence of laryngeal cancer and exposure to acid mists.
Br J Ind Med 45: 766-776.
Tanaka H, Hirose M, Hagiwara A, Imaida K, Shirai T,
Ito N (1995). Rat strain differences in catechol carcinogenicity
to the stomach. Food Chem Toxicol 33: 93-98.
U.S. Environmental Protection Agency (U.S. EPA, 1997a).
Cancer Assessment Document. Evaluation of the Carcinogenic Potential
of Ethoprop. Cancer Assessment Review Committee. Health Effects
Division. Office of Pesticide Programs. September 25, 1997.
U.S. Environmental Protection Agency (U.S. EPA, 1997b).
Memorandum: Carcinogenicity Peer Review of Propachlor. Office of
Prevention, Pesticides and Toxic Substances. October 16, 1997.
U.S. Environmental Protection Agency (U.S. EPA, 1997c).
Memorandum: Carcinogenicity Peer Review of Tribufos (DEF). Office
of Prevention, Pesticides and Toxic Substances. May 22,
You will need the free program Adobe Acrobat Reader to view or
print PDF files 
For questions regarding Proposition 65, please contact the Cynthia
Oshita in the Proposition 65 Implementation Program
For help with this web site please contact the Web
Mistress
|